Leiden, The Netherlands, October 17th, 2011 – ISA Pharmaceuticals, a leader in the development of novel immunotherapeutic products for oncology and infectious diseases, today announced that Professor Jan van de Winkel has joined its Supervisory Board.
“We are excited to have Jan van de Winkel strengthening our Supervisory Board. He complements an experienced and motivated team, the collective experience of which spans the biotechnological, pharmaceutical and financial areas. We expect ISA to benefit from his insights and expertise and look forward to interacting with Jan to further propel the company in the rapidly emerging field of immunotherapy.” says Gerard Platenburg, managing director of ISA Pharmaceuticals BV. Professor van de Winkel has built a distinguished track record in the pharmaceutical industry over the last 25 years. Currently, he serves as CEO of Genmab A/S, a leading company in antibody therapeutics. Prior to co-founding Genmab, Professor van de Winkel served as Scientific Director and Vice President of Medarex Europe.
ISA Pharmaceuticals is dedicated to fighting cancer and infectious diseases by providing novel immunotherapeutics based on its proprietary SLP® technology to activate and employ the patient’s own immune system. Its most advanced product is a highly efficacious therapeutic vaccine against HPV-induced lesions. The company was founded in 2004 by Aglaia Oncology Fund and has its roots in the ground-breaking research of the internationally renowned tumor immunologist Professor Kees Melief. For more information, please contact Gerard Platenburg (+31 (0) 6 53439090) or visit our website at: www.isa-pharma.com